XIAOFAN LI: Open Payments
NPI 1962631085 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$262 in 9 payments from 5 companies in 2025. Trend: 2023 $466 · 2024 $307 · 2025 $262
Food & beverage: $262
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $141 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Lundbeck LLC | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: INGREZZA, AUSTEDO XR, REXULTI, COBENFY, UZEDY, CAPLYTA.
Industry payments across TX — which companies pay providers there.
